systematic_review
2024
Supplementation with NAD+ Precursors for Treating Alzheimer's Disease: A Metabolic Approach
Unknown authors
Published in J Alzheimers Dis
Key Findings
NAD+ precursors show preclinical promise for amyloid and mitochondrial pathways, but human evidence remains preliminary.
Conclusions
Mechanistic interest without clinical proof.
Supplements Studied
NMN
Compound
NAD+ precursors show preclinical promise for amyloid and mitochondrial pathways, but human evidence remains preliminary.
Outcomes Measured
NAD+ precursors show preclinical promise for amyloid and mitochondrial pathways, but human evidence remains preliminary.
Maintenance on intracellular levels of nicotinamide adenine dinucleotide (NAD+) has been reported to be a promising therapeutic strategy for the treatment of AD.
Related Health Concerns
Study Details
Year:2024
Quality Score:5/10
Access Study
This information is for educational purposes only. Always consult a healthcare professional before starting any supplement regimen.